A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in NNMO and NMOSD

This study is not currently open for recruitment.

Study Sponsor: Astrazeneca/MedImmune/Vielabio

Clinical Trials.Gov Identifier: NCT02200770